ClinicalTrials.gg
RecruitingNCT05791864Updated Oct 14, 2026

A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease

A Phase 1/2 interventional study of TTX-381 and TTX-381 in Neuronal Ceroid Lipofuscinosis Type 2, sponsored by Tern Therapeutics, LLC. Recruiting at 2 sites in 2 countries. Open to participants aged 24 Months to 84 Months. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Tern Therapeutics, LLC · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 14, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
24 Months to 84 Months
Sex
All
01

Study summary

This is a registrational, first-in-human, open-label, dose escalation and expansion study evaluating the safety, tolerability and effectiveness of TTX-381, administered by injection under the retina, for the treatment of eye problems caused by CLN2 (Batten disease). The study includes dose escalation and expansion groups evaluating treatment in one or both eyes. Participants are followed for 5 years after treatment to assess safety and clinical outcomes.

Read the detailed description

This is a registrational, first-in-human, open-label, dose escalation and expansion study of TTX-381, a gene therapy for the potential treatment of ocular manifestations of CLN2 (Batten disease). TTX-381 is being studied as a potential treatment for the eye and vision problems associated with neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

Children with CLN2 disease have a non-working gene (set of instructions) that causes an enzyme called tripeptidyl-peptidase 1 (TPP1) to be missing or not work properly in their bodies. Without enough TPP1, cells cannot break down certain materials, causing them to build up and damage cells, particularly the central nervous system (the brain and spine) and retina (eyes). This can lead to seizures, changes in development and thinking and vision loss.

The study includes dose-escalation and expansion cohorts evaluating treatment in one or both eyes. In participants receiving treatment in one eye, the untreated fellow eye serves as the control because CLN2-related eye disease progresses similarly in both eyes. In the bilateral treatment cohort, both eyes receive TTX-381.

Participants will be followed in this study for 5 years after TTX-381 administration.

02

Conditions studied

  • Neuronal Ceroid Lipofuscinosis Type 2

Keywords

  • CLN2
  • Batten Disease
  • Gene Therapy
  • Adeno-associated virus
  • AAV
03

In context

Neuronal Ceroid-Lipofuscinoses

49 studies on the registry are indexed under Neuronal Ceroid-Lipofuscinoses; 13 are open to participants now.

This study's planned enrollment of 26 is above the median of 13 across 22 interventional studies indexed under Neuronal Ceroid-Lipofuscinoses.

Browse Neuronal Ceroid-Lipofuscinoses studies →

Lead sponsor

This is the only study on the registry with Tern Therapeutics, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
24 Months to 84 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  • Biallelic CLN2 mutations.
  • Decreased leukocyte TPP1 activity.
  • Clinical signs or symptoms consistent with CLN2 disease, such as developmental delay or decline, seizures, vision loss, or an older sibling with confirmed CLN2 diagnosis.
  • Currently receiving biweekly ICV ERT treatment with cerliponase alfa.
  • Age ≥24 month and ≤84 months at screening
  • In the phase of accelerated decline in CRT with the following baseline retinal criteria confirmed by the central reading center:

    1. CRT ≤210 μm and
    2. CRT ≥140 μm in both eyes and
  • Is willing and able to comply with the protocol and 5-year visit schedule.

Written must be provided by the participants parent(s) or legally authorized representative(s)

Exclusion criteria

Exclusion Criteria:

Participants will be excluded if any of the following criteria apply:

  • Any ocular or systemic condition that, in the investigator's opinion, would prevent administration or evaluation of TTX-381, interfere with interpretation of participant safety or study results or make the participant unsuitable for the study. (eg, significant lens or corneal opacities, glaucoma, amblyopia, gross retinal anatomical abnormality, etc).
  • Difference in CRT measurement between the right and left eye >10μm at screening
  • Prior Grade 3 or 4 reaction, to ICV cerliponase alfa infusion. (eg, bronchospasm and hypotension requiring intravenous treatment, cardiac dysfunction, anaphylaxis)
  • Any that would prevent continued administration of ICV cerliponase alfa, including ventriculo-peritoneal shunt, acute intracerebroventricular access device leakage, device failure, or device-related infection.
  • Prior participation in a gene therapy study.
  • Prior participation in another ocular clinical trial, except an intravitreal cerliponase alfa trial where a subject has received a maximum of 3 injections and the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study after a of 3 or more months.
  • Prior intraocular injections of any kind, except prior treatment with an maximum of 3 ICV injections of cerliponase alfa if at least 3 months have passed since last injection.
  • Participation in a nonocular clinical study with an drug within 6 months prior to screening, except for intracerebroventricular cerliponase alfa.
  • Ocular surgery within 6 months prior to screening.
  • Prior bone marrow transplant.
  • Use of the following medications within the 30 days prior to treatment: gemfibrozil, mycophenolate, prednisone or other for the intended purpose of treating NCL (Steroid treatment for asthma is not excluded),
  • Known sensitivity or contraindications to medications planned for use in the peri-operative period.
  • Contraindications to systemic .
  • Severe renal insufficiency as determined by an estimated (eGFR) \< 30 mL/min/1.73 m2, based on creatinine, at Screening
  • Severe hepatic insufficiency as determined by (ALT) or aspartate aminotransferase (AST) > 3 × (ULN) or total > 1.5 × ULN at Screening Visit 1, unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin \< 35% of total bilirubin.
  • Mutations in another CLN gene.
  • Mutation in another gene associated with inherited retinal disease.
  • Contraindications to intraocular surgery (eg, severe coagulopathy).
  • Positive urine pregnancy test at Screening (applying only to females of ).
  • Any other condition that would not allow the potential participant to complete follow-up examinations during the study or, in the opinion of the investigator, makes the potential participant unsuitable for the study.
  • The participant had a positive polymerase chain reaction (PCR) viral test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2 PCR) within the last 4 weeks before signing the form (ICF) or has persistent coronavirus disease (COVID-19) symptoms regardless of when the last SARS-CoV2 PCR viral test was performed or when the infection occurred.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level 1

    2×10\^10 GC/eye

    Genetic: TTX-381

  • Experimental
    Cohort 2: Dose Level 2

    6×10\^10 GC/eye

    Genetic: TTX-381

  • Experimental
    Cohort 3: Expansion Cohort

    2×10\^10 GC/eye

    Genetic: TTX-381

  • Experimental
    Cohort 4: Bilateral Administration

    2×10\^10 GC/eye administered once per eye

    Genetic: TTX-381

Interventions

  • GeneticTTX-381

    Gene Therapy (AAV9.CB7.hCLN2): One time subretinal dose in study eye

  • GeneticTTX-381

    Gene Therapy (AAV9.CB7.hCLN2): One time subretinal dose in each eye

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of TTX-381 through Day 360

    Safety and tolerability will be assessed based on ocular and systemic adverse events and serious adverse events following administration of TTX-381.- ALL REGIONS

    Time frame: 360 days

  2. Rate of change in area of Ellipsoid Zone (EZ) loss through Day 180

    The rate of change in area of EZ loss will be assessed using spectral-domain optical coherence tomography (SD-OCT). - US

    Time frame: Day 180

Secondary outcomes

  1. Area of EZ Loss at Day 180 and Day 360

    To evaluate the effect of TTX-381 on area of EZ loss as measured by SD-OCT- UK/EU

    Time frame: Day 180, Day 360

  2. Central subfield photoreceptor layer thickness

    To evaluate the effect of TTX-381 on central subfield photoreceptor layer thickness as measured by SD-OCT; Day 180- UK/EU and Day 360- All Regions

    Time frame: Day 180, Day 360

  3. TTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) Aqueous Humor (AH) Concentration ≤78 ng/ml

    The proportion of treated eyes with TPP1 concentration in aqueous humor greater than or equal to 78 ng/mL will be assessed. - US

    Time frame: Day 90

  4. TTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) Aqueous Humor (AH) Concentration

    TTX-381 transgene product (tripeptidyl peptidase 1 \[TPP1\]) will be measured in aqueous humor. - UK/EU

    Time frame: Day 90 & Day 360

  5. Vector Shedding

    To evaluate shedding of TTX-381 in urine and tears Secondary- UK/EU Exploratory-US

    Time frame: Day 360

07

Study locations

2 of 2 sites recruiting
  • University Medical Center Hamburg-Eppendorf (UKE)- Childrens Hospital
    Hamburg, Germany
    Recruiting
    • Prof. Dr. med. Angela Schulz · Contactncl-sprechstunde@uke.de · +49 (0)40 7410-20440
    • Prof. Dr. med. Angela Schulz · Principal investigator
  • Greater Ormond Street Hospital
    London, Wc1N 3JH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2026 → Dec 2026 and completion Jul 2031 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Mar 30, 2023
StartActual
May 17, 2023
Primary completionEst.
Dec 2026was Jul 2026
CompletionEst.
Dec 2031was Jul 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2026→Dec 2026
Oct 14, 2026
Study completion
Jul 30, 2031→Dec 2031
Oct 14, 2026
Enrollment
16→26
Oct 14, 2026
Eligibility
Minimum age 12 Months→24 Months; 10 inclusion criteria edited, 1 added, 6 removed; 10 exclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • ChangedBefore A participant is eligible to be included in the study only if all of the following criteria apply:Now Participants must meet all of the following criteria:
  • EditedHas biallelicBiallelic CLN2 mutations.
  • EditedHas decreasedDecreased leukocyte TPP1 activity.
  • EditedHas clinicalClinical signs or symptoms consistent with CLN2 disease (eg,, such as developmental delay, developmental or decline, seizureseizures, vision loss, or other signs/symptoms) OR an older sibling with confirmed CLN2 diagnosis.
  • EditedIs currentlyCurrently receiving biweekly ICV ERT treatment with cerliponase alfa.
  • RemovedMeets the following baseline disease condition according to age and CRT as assessed by SD-OCT and confirmed by CRC:
  • EditedAge ≥24 month and ≤84 months, at screening
  • EditedParticipants inIn the phase of accelerated decline in CRT with the following baseline retinal criteria confirmed by the central reading center:
  • EditedCRT at baseline ≤210 μm and
  • EditedCRT at baseline ≥140 μm in both eyes and
  • EditedIs willing and able to adhere tocomply with the protocol and 5-year visit schedule.
  • RemovedSexually active female participants of childbearing potential (following menarche) or fertile male participants (following puberty) must be willing to use a medically accepted form of contraception from Screening Visit 2 until 6 weeks after vector administration.
  • RemovedOR
  • RemovedWas previously administered TTX-381.
  • RemovedUpon retrospective review, met the above criteria at the time of administration of TTX-381. IDMC may consider exceptions to this when weighing whether to retrospectively enroll a participant who has received TTX-381.
  • RemovedHas been recommended for enrollment into the clinical trial by IDMC
  • AddedWritten informed consent must be provided by the participants parent(s) or legally authorized representative(s)
Exclusion criteria
  • EditedParticipants arewill be excluded from the study if any of the following criteria apply:
  • EditedAny ocular or systemic condition that, in the investigator's opinion of the investigator, would prevent administration andor evaluation of the investigational product orTTX-381, interfere with interpretation of participant safety or study results or make the participant unsuitable for the study. (eg, significant lens or corneal opacities, glaucoma, amblyopia, gross retinal anatomical abnormality, etc).
  • EditedDifference in screening CRT measurement between the right and left eye >10μm. at screening
  • EditedPrior Grade 3 or 4 hypersensitivity reaction, to ICV cerliponase alfa infusion. (eg, bronchospasm and hypotension requiring intravenous treatment, cardiac dysfunction, anaphylaxis to ICV cerliponase alfa infusion.)
  • EditedAny other contraindication to thethat would prevent continued administration of ICV cerliponase alfa, including ventriculo-peritoneal shunt, acute intracerebroventricular access device leakage, device failure, or device-related infection that would impact ability to receive ICV cerliponase alfa.
  • ChangedBefore Prior participation in a gene therapy study. A subject who has received subretinal TTX-381 under a compassionate use protocol may be enrolled if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study and the IDMC has approved their enrollment.Now Prior participation in a gene therapy study.
  • ChangedBefore Prior intraocular injections of any kind, with the following two exceptions. A subject who has received a maximum of 3 intravitreal injections of cerliponase alfa may be enrolled in the study if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study after a washout period of 3 or more months. A subject who has received subretinal TTX-381 under a compassionate use protocol may be enrolled if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study and the IDMC has approved their enrollment.Now Prior intraocular injections of any kind, except prior treatment with an maximum of 3 ICV injections of cerliponase alfa if at least 3 months have passed since last injection.
  • EditedParticipation in a nonocular clinical study with an investigational drug in the pastwithin 6 months prior to screening, except for intracerebroventricular cerliponase alfa.
  • RemovedOcular surgery within the prior 6 months except as above for subretinal TTX-381 administration.
  • AddedOcular surgery within 6 months prior to screening.
  • AddedPrior bone marrow transplant.
  • EditedPrior bone marrow transplant. Use of the following medications within the 30 days prior to treatment: gemfibrozil, mycophenolate, prednisone or other steroids for the intended purpose of treating NCL (not includingSteroid treatment for asthma indicationsis not excluded), flupirtine.
  • EditedSevere renal insufficiency as determined by an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, based on creatinine, at Screening. If the laboratory determines that the creatinine level is less than the lower limit of assay validation or detection, then the lowest limit cutoff value will be used to estimate eGFR.
Oct 14, 2026
Interventions
Added Genetic: TTX-381. Arm changed Cohort 2: Main Treatment Arm→Cohort 2: Dose Level 2; Expansion Cohort→Cohort 3: Expansion Cohort. Arms added: Cohort 1: Dose Level 1·Cohort 4: Bilateral Administration; arms removed: Cohort 1: Main Treatment Arm
Oct 14, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedSafety and tolerability of TTX-381 through Day 360Time frame: 360 days
  • AddedRate of change in area of Ellipsoid Zone (EZ) loss through Day 180Time frame: Day 180
  • RemovedOcular and overall AE and SAEs through Day 360Time frame: 360 days
Oct 14, 2026
Secondary outcomes
2 edited, 3 added, 2 removed
What changed in the outcomes
  • EditedTo evaluate the effect of TTX-381 on centralCentral subfield photoreceptor layer thicknessTime frame: Day 180, Day 360
  • EditedTo measure TTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) in aqueous humorAqueous Humor (AH) Concentration ≤78 ng/mlTime frame: Day 90, Day 360 → Day 90
  • AddedArea of EZ Loss at Day 180 and Day 360Time frame: Day 180, Day 360
  • AddedTTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) Aqueous Humor (AH) ConcentrationTime frame: Day 90 & Day 360
  • AddedVector SheddingTime frame: Day 360
  • RemovedTo evaluate the effect of TTX-381 on area of EZ lossTime frame: Day 180, Day 360
  • RemovedTo evaluate shedding of TTX-381 in urine and tearsTime frame: Day 360
Oct 14, 2026
Title
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease→A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Jul 30, 2026→Dec 2026
    Study completion Jul 30, 2031→Dec 2031
    Enrollment 16→26
    Eligibility Minimum age 12 Months→24 Months; 10 inclusion criteria edited, 1 added, 6 removed; 10 exclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore A participant is eligible to be included in the study only if all of the following criteria apply:Now Participants must meet all of the following criteria:
    • EditedHas biallelicBiallelic CLN2 mutations.
    • EditedHas decreasedDecreased leukocyte TPP1 activity.
    • EditedHas clinicalClinical signs or symptoms consistent with CLN2 disease (eg,, such as developmental delay, developmental or decline, seizureseizures, vision loss, or other signs/symptoms) OR an older sibling with confirmed CLN2 diagnosis.
    • EditedIs currentlyCurrently receiving biweekly ICV ERT treatment with cerliponase alfa.
    • RemovedMeets the following baseline disease condition according to age and CRT as assessed by SD-OCT and confirmed by CRC:
    • EditedAge ≥24 month and ≤84 months, at screening
    • EditedParticipants inIn the phase of accelerated decline in CRT with the following baseline retinal criteria confirmed by the central reading center:
    • EditedCRT at baseline ≤210 μm and
    • EditedCRT at baseline ≥140 μm in both eyes and
    • EditedIs willing and able to adhere tocomply with the protocol and 5-year visit schedule.
    • RemovedSexually active female participants of childbearing potential (following menarche) or fertile male participants (following puberty) must be willing to use a medically accepted form of contraception from Screening Visit 2 until 6 weeks after vector administration.
    • RemovedOR
    • RemovedWas previously administered TTX-381.
    • RemovedUpon retrospective review, met the above criteria at the time of administration of TTX-381. IDMC may consider exceptions to this when weighing whether to retrospectively enroll a participant who has received TTX-381.
    • RemovedHas been recommended for enrollment into the clinical trial by IDMC
    • AddedWritten informed consent must be provided by the participants parent(s) or legally authorized representative(s)
    Exclusion criteria
    • EditedParticipants arewill be excluded from the study if any of the following criteria apply:
    • EditedAny ocular or systemic condition that, in the investigator's opinion of the investigator, would prevent administration andor evaluation of the investigational product orTTX-381, interfere with interpretation of participant safety or study results or make the participant unsuitable for the study. (eg, significant lens or corneal opacities, glaucoma, amblyopia, gross retinal anatomical abnormality, etc).
    • EditedDifference in screening CRT measurement between the right and left eye >10μm. at screening
    • EditedPrior Grade 3 or 4 hypersensitivity reaction, to ICV cerliponase alfa infusion. (eg, bronchospasm and hypotension requiring intravenous treatment, cardiac dysfunction, anaphylaxis to ICV cerliponase alfa infusion.)
    • EditedAny other contraindication to thethat would prevent continued administration of ICV cerliponase alfa, including ventriculo-peritoneal shunt, acute intracerebroventricular access device leakage, device failure, or device-related infection that would impact ability to receive ICV cerliponase alfa.
    • ChangedBefore Prior participation in a gene therapy study. A subject who has received subretinal TTX-381 under a compassionate use protocol may be enrolled if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study and the IDMC has approved their enrollment.Now Prior participation in a gene therapy study.
    • ChangedBefore Prior intraocular injections of any kind, with the following two exceptions. A subject who has received a maximum of 3 intravitreal injections of cerliponase alfa may be enrolled in the study if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study after a washout period of 3 or more months. A subject who has received subretinal TTX-381 under a compassionate use protocol may be enrolled if the PI, Medical Monitor, and Sponsor all agree that he/she can safely and successfully participate in the study and the IDMC has approved their enrollment.Now Prior intraocular injections of any kind, except prior treatment with an maximum of 3 ICV injections of cerliponase alfa if at least 3 months have passed since last injection.
    • EditedParticipation in a nonocular clinical study with an investigational drug in the pastwithin 6 months prior to screening, except for intracerebroventricular cerliponase alfa.
    • RemovedOcular surgery within the prior 6 months except as above for subretinal TTX-381 administration.
    • AddedOcular surgery within 6 months prior to screening.
    • AddedPrior bone marrow transplant.
    • EditedPrior bone marrow transplant. Use of the following medications within the 30 days prior to treatment: gemfibrozil, mycophenolate, prednisone or other steroids for the intended purpose of treating NCL (not includingSteroid treatment for asthma indicationsis not excluded), flupirtine.
    • EditedSevere renal insufficiency as determined by an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, based on creatinine, at Screening. If the laboratory determines that the creatinine level is less than the lower limit of assay validation or detection, then the lowest limit cutoff value will be used to estimate eGFR.
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedSafety and tolerability of TTX-381 through Day 360Time frame: 360 days
    • AddedRate of change in area of Ellipsoid Zone (EZ) loss through Day 180Time frame: Day 180
    • RemovedOcular and overall AE and SAEs through Day 360Time frame: 360 days
    Secondary outcomes 2 edited, 3 added, 2 removed
    What changed in the outcomes
    • EditedTo evaluate the effect of TTX-381 on centralCentral subfield photoreceptor layer thicknessTime frame: Day 180, Day 360
    • EditedTo measure TTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) in aqueous humorAqueous Humor (AH) Concentration ≤78 ng/mlTime frame: Day 90, Day 360 → Day 90
    • AddedArea of EZ Loss at Day 180 and Day 360Time frame: Day 180, Day 360
    • AddedTTX-381 transgene product (tripeptidyl peptidase 1 [TPP1]) Aqueous Humor (AH) ConcentrationTime frame: Day 90 & Day 360
    • AddedVector SheddingTime frame: Day 360
    • RemovedTo evaluate the effect of TTX-381 on area of EZ lossTime frame: Day 180, Day 360
    • RemovedTo evaluate shedding of TTX-381 in urine and tearsTime frame: Day 360
    Interventions Added Genetic: TTX-381. Arm changed Cohort 2: Main Treatment Arm→Cohort 2: Dose Level 2; Expansion Cohort→Cohort 3: Expansion Cohort. Arms added: Cohort 1: Dose Level 1·Cohort 4: Bilateral Administration; arms removed: Cohort 1: Main Treatment Arm
    Title A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease→A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
    + 5 other changes: verification date, description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05791864
Lead sponsor
Tern Therapeutics, LLC
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
May 17, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Tern Therapeutics Patient Advocacy
Contact
patientadvocacy@terntx.com
202-644-8488

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion